Zeitview Acquires Heliolytics, Becoming the Market Leader in Solar Aerial Inspections
6.9.2023 13:00:00 EEST | Business Wire | Press release
Zeitview today takes the lead in advanced aerial inspections for energy and infrastructure by acquiring Heliolytics, which specializes in photovoltaic (PV) system performance via aerial inspection and integrated analytics. The acquisition of this former division of NovaSource Power Services enables the combining of Heliolytics' data insights with Zeitview’s expertise in aerial inspection technologies. The majority of Heliolytics staff will join Zeitview, and the team’s presence in Toronto, Canada, will continue. The amount of the deal was not disclosed.
"Heliolytics are pioneers in the solar industry and have earned a commendable reputation for their unwavering commitment to quality, precision, and exceptional customer service—values we hold in the highest esteem,” said Dan Burton, founder and Chief Executive Officer at Zeitview. “Their expertise and dedication are valuable as we continue developing groundbreaking solutions that redefine inspection standards within the renewable energy sector. We are excited for this next chapter in our journey, where our united teams create a complete market-winning solution."
For renewable energy customers, this collaboration reinforces Zeitview's multi-asset approach to solar, wind, and utilities. For property owners, it offers critical insights into the performance of their rooftop solar facilities. For all customers, Heliolytics' international operations in Europe, Latin America, and the Asian Pacific are also being combined with Zeitview's global footprint in those same regions.
“Joining forces with Zeitview is a tremendous opportunity to further the renewable energy industry,” said Jocelyne Moyer, Head of Heliolytics. Post-acquisition, Moyer takes the title of Senior Director of Strategy and Operations at Zeitview. “We have a shared commitment with Zeitview to deep client partnerships, science-driven innovation, and unparalleled responsiveness to our global clients. I am excited to join the leadership team and look forward to collaborations that will strengthen Zeitview’s role in the operations and maintenance of renewable energy assets.”
Heliolytics' inspection tools and integrated analytics are now supported by Zeitview's AI/ML data processing engine. With this addition, Zeitview doubles the reach and breadth of its airplane operations and adds topography, EPC, and drone solutions to Heliolytics, all of which can translate into faster, more comprehensive customer results.
With the sale of Heliolytics to Zeitview, NovaSource Power Services continues to offer best-in-class aerial inspection software and services to their customers via Zeitview.
“We are thrilled to continue our longstanding partnership with the Heliolytics team under the Zeitview name,” said Timo Moeller, Chief Growth Officer, NovaSource Power Services. “Zeitview’s impressive inspection and software tools will enhance the insights we currently use to support operations and maintenance requests. It is clear that the Zeitview team deeply understands our data needs and is committed to providing continued unrivaled expertise as aerial inspection providers to support our growth.”
A complete integration of Heliolytics operations, data capture, and software into Zeitview’s market-leading global solar solution is expected to be finished by the end of 2024.
To learn more about how Zeitview supports global energy and infrastructure through advanced inspections and actionable data, visit www.zeitview.com.
ABOUT ZEITVIEW
As a single partner for aerial inspections across a broad spectrum of industries, including solar, wind, real estate, telecom, and utility assets, Zeitview is trusted by the largest enterprises worldwide to deliver fast, accurate insights that optimize asset performance and reduce operating and maintenance costs. Combining state-of-the-art aerial inspection software with the ability to capture in-depth visual data via airplanes and drones, Zeitview harnesses the power of artificial intelligence and machine learning. Such aerial intelligence delivers customers actionable insights in near real-time and empowers organizations to make better-informed decisions about their most critical assets at scale.
Learn more about Zeitview's cutting-edge solutions at www.zeitview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906378784/en/
Contact information
Technica Communications for Zeitview
Cait Caviness
zeitview@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
